{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:55:09Z","timestamp":1790412909318,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the association between time to biochemical recurrence (ttBCR) and cancer-specific mortality (CSM) after prostatectomy or radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This population-based study included 3606 patients experiencing BCR after prostatectomy or radiotherapy in Stockholm, Sweden, between 2003 and 2019. We tested the association between ttBCR and CSM using Cox models adjusted for clinical and pathological characteristics and estimated conditional cancer-specific survival by ttBCR and EAU risk group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among prostatectomy (n\u2009=\u20092392) vs radiotherapy patients (n\u2009=\u20091214), 589 vs 170 (25 vs 14%), 1205 vs 387 (50 vs 32%), 598 vs 657 (25 vs 54%) were low, intermediate, and high EAU risk group, respectively. The median ttBCR was 29 (interquartile range (IQR):11, 58) and 33\u00a0months (IQR:16, 60) among prostatectomy and radiotherapy patients, respectively. At a median follow-up for survivors of 52\u00a0months after BCR, 823 patients died, including 394 of PCa (104 in the prostatectomy and 290 in the radiotherapy group). At Cox multivariable models, ttBCR was associated with CSM in prostatectomy patients (HR:0.87; p:0.012) and radiotherapy patients (HR:0.69; p\u2009&lt;\u20090.001). Adjusted cancer-specific survival probability was strongly influenced by ttBCR and EAU risk group. For instance, intermediate-risk patients with BCR after prostatectomy had a 10-year survival probability ranging from 0.74 to 0.98 for a ttBCR of 0 to 10\u00a0years. Limitations included the retrospective nature of the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings demonstrate a strong association between ttBCR and CSM. These results suggest that ttBCR should be used to risk-stratify patients experiencing BCR after either RP or RT. The high survival probability observed in low- and intermediate-risk PCa patients who experience BCR after a prolonged period post-treatment should inform decisions regarding the intensity and duration of oncological follow-up for these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-026-06231-5","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T12:27:54Z","timestamp":1770294474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Time to BCR and cancer-specific mortality after radiotherapy or prostatectomy: implications for risk stratification and follow-up"],"prefix":"10.1007","volume":"44","author":[{"given":"Francesco","family":"Pellegrino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Grauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo Giovanni","family":"Falagario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Akre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Aly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Gr\u00f6nberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Egevad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ash","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter N.","family":"Wiklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"6231_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17\u201348","journal-title":"CA Cancer J Clin"},{"key":"6231_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 86:148\u2013163","journal-title":"Eur Urol"},{"key":"6231_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/JU.0000000000002757","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW et al (2022) Clinically localized prostate cancer: AUA\/ASTRO guideline, Part I: introduction, risk assessment, staging, and risk-based management. J Urol 208:10\u201318","journal-title":"J Urol"},{"key":"6231_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2021","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J et al (2021) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 86:164\u2013182","journal-title":"Eur Urol"},{"key":"6231_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000000295","volume":"202","author":"TM Pisansky","year":"2019","unstructured":"Pisansky TM, Thompson IM, Valicenti RK, D\u2019Amico AV, Selvarajah S (2019) Adjuvant and salvage radiotherapy after prostatectomy: ASTRO\/AUA guideline amendment 2018-2019. J Urol 202:533\u2013538","journal-title":"J Urol"},{"key":"6231_CR6","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach","year":"2006","unstructured":"Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Oncol Biol Phys 65:965\u2013974","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6231_CR7","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591\u20131597","journal-title":"JAMA"},{"key":"6231_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.32900","volume":"6","author":"UG Falagario","year":"2023","unstructured":"Falagario UG, Abbadi A, Remmers S, Bj\u00f6rnebo L, Bogdanovic D, Martini A et al (2023) Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy. JAMA Netw Open 6:e2332900","journal-title":"JAMA Netw Open"},{"issue":"4","key":"6231_CR9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.euo.2023.08.005","volume":"7","author":"UG Falagario","year":"2023","unstructured":"Falagario UG, Knipper S, Pellegrino F, Martini A, Akre O, Egevad L et al (2023) Prostate cancer-specific and all-cause mortality after robot-assisted radical prostatectomy: 20 years\u2019 report from the European association of urology robotic urology section scientific working group. Eur Urol Oncol 7(4):705\u2013712","journal-title":"Eur Urol Oncol"},{"key":"6231_CR10","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL et al (2023) Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 388:1547\u20131558","journal-title":"N Engl J Med"},{"key":"6231_CR11","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","volume":"396","author":"CC Parker","year":"2020","unstructured":"Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C et al (2020) Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet 396:1413\u20131421","journal-title":"Lancet"},{"key":"6231_CR12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","volume":"17","author":"C Carrie","year":"2016","unstructured":"Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I et al (2016) Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 17:747\u2013756","journal-title":"Lancet Oncol"},{"key":"6231_CR13","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.eururo.2019.03.016","volume":"75","author":"D Tilki","year":"2019","unstructured":"Tilki D, Preisser F, Graefen M, Huland H, Pompe RS (2019) External validation of the European association of urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a European cohort. Eur Urol 75:896\u2013900","journal-title":"Eur Urol"},{"key":"6231_CR14","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","volume":"75","author":"T Van den Broeck","year":"2019","unstructured":"Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E et al (2019) Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol 75:967\u2013987","journal-title":"Eur Urol"},{"key":"6231_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejca.2015.11.004","volume":"54","author":"P Dell'Oglio","year":"2016","unstructured":"Dell\u2019Oglio P, Suardi N, Boorjian SA, Fossati N, Gandaglia G, Tian Z et al (2016) Predicting survival of men with recurrent prostate cancer after radical prostatectomy. Eur J Cancer 54:27\u201334","journal-title":"Eur J Cancer"},{"issue":"163","key":"6231_CR16","first-page":"e7","volume":"33","author":"A Briganti","year":"2015","unstructured":"Briganti A, Karnes RJ, Gandaglia G, Spahn M, Gontero P, Tosco L et al (2015) Natural history of surgically treated high-risk prostate cancer. Urol Oncol 33(163):e7-13","journal-title":"Urol Oncol"},{"key":"6231_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.eururo.2013.03.006","volume":"64","author":"F Abdollah","year":"2013","unstructured":"Abdollah F, Boorjian S, Cozzarini C, Suardi N, Sun M, Fiorino C et al (2013) Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification. Eur Urol 64:557\u2013564","journal-title":"Eur Urol"},{"key":"6231_CR18","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1001\/jama.299.23.2760","volume":"299","author":"BJ Trock","year":"2008","unstructured":"Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW et al (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299:2760\u20132769","journal-title":"JAMA"},{"key":"6231_CR19","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.eururo.2014.09.028","volume":"67","author":"ZS Zumsteg","year":"2015","unstructured":"Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Polkinghorn W et al (2015) The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol 67:1009\u20131016","journal-title":"Eur Urol"},{"key":"6231_CR20","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1002\/cncr.28202","volume":"119","author":"MB Kim","year":"2013","unstructured":"Kim MB, Chen MH, de Castro M, Loffredo M, Kantoff PW, D\u2019Amico AV (2013) Defining the optimal approach to the patient with postradiation prostate-specific antigen recurrence using outcome data from a prospective randomized trial. Cancer 119:3280\u20133286","journal-title":"Cancer"},{"key":"6231_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ijrobp.2007.05.047","volume":"70","author":"MK Buyyounouski","year":"2008","unstructured":"Buyyounouski MK, Hanlon AL, Horwitz EM, Pollack A (2008) Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys 70:59\u201366","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6231_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/21681805.2020.1739139","volume":"54","author":"M Aly","year":"2020","unstructured":"Aly M, Leval A, Schain F, Liwing J, Lawson J, V\u00e1g\u00f3 E et al (2020) Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden. Scand J Urol 54:115\u2013121","journal-title":"Scand J Urol"},{"key":"6231_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","volume":"32","author":"HL Brooke","year":"2017","unstructured":"Brooke HL, Talb\u00e4ck M, H\u00f6rnblad J, Johansson LA, Ludvigsson JF, Druid H et al (2017) The Swedish cause of death register. Eur J Epidemiol 32:765\u2013773","journal-title":"Eur J Epidemiol"},{"key":"6231_CR24","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jclinepi.2014.11.022","volume":"68","author":"D Nieboer","year":"2015","unstructured":"Nieboer D, Vergouwe Y, Roobol MJ, Ankerst DP, Kattan MW, Vickers AJ et al (2015) Nonlinear modeling was applied thoughtfully for risk prediction: the prostate biopsy collaborative group. J Clin Epidemiol 68:426\u2013434","journal-title":"J Clin Epidemiol"},{"key":"6231_CR25","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1002\/cncr.26169","volume":"117","author":"MR Cooperberg","year":"2011","unstructured":"Cooperberg MR, Hilton JF, Carroll PR (2011) The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 117:5039\u20135046","journal-title":"Cancer"},{"key":"6231_CR26","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.eururo.2011.02.026","volume":"59","author":"SA Boorjian","year":"2011","unstructured":"Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML et al (2011) Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 59:893\u2013899","journal-title":"Eur Urol"},{"key":"6231_CR27","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.juro.2006.06.017","volume":"176","author":"SJ Freedland","year":"2006","unstructured":"Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW (2006) Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 176:1404\u20131408","journal-title":"J Urol"},{"key":"6231_CR28","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s10147-019-01463-5","volume":"24","author":"S Pak","year":"2019","unstructured":"Pak S, You D, Jeong IG, Kim YS, Hong JH, Kim CS et al (2019) Time to biochemical relapse after radical prostatectomy and efficacy of salvage radiotherapy in patients with prostate cancer. Int J Clin Oncol 24:1238\u20131246","journal-title":"Int J Clin Oncol"},{"key":"6231_CR29","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1002\/cncr.26498","volume":"118","author":"NS Kapadia","year":"2012","unstructured":"Kapadia NS, Olson K, Sandler HM, Feng FY, Hamstra DA (2012) Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancer. Cancer 118:2059\u20132068","journal-title":"Cancer"},{"key":"6231_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.euo.2023.05.006","volume":"7","author":"UG Falagario","year":"2024","unstructured":"Falagario UG, Martini A, Pellegrino F, Carrieri G, Manon M, Lantz A et al (2024) Re: Derya Tilki, Ming-Hui Chen, Jing Wu, et al. Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death. J Clin Oncol 2023;41:2428-35. Eur Urol Oncol 7:167\u2013168","journal-title":"Eur Urol Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06231-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06231-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06231-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:36:25Z","timestamp":1781631385000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06231-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6231"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06231-5","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This cohort study was approved by the Regional Ethics Board in Stockholm, Sweden, and informed consent was waived because deidentified retrospective data from a population-based registry was used.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"149"}}